Hepatitis D future or investigational therapies

Hepatitis Main Page
Hepatitis D
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Hepatitis D from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Hepatitis D future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hepatitis D future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hepatitis D future or investigational therapies
CDC on Hepatitis D future or investigational therapies
Hepatitis D future or investigational therapies in the news
Blogs on Hepatitis D future or investigational therapies
Directions to Hospitals Treating Hepatitis D
Risk calculators and risk factors for Hepatitis D future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]

Future or Investigational Therapies

Although the lack of viral enzymes represents a challenge in the development of antiviral drugs, the life cycle of HDV relies deeply on postranslational modification and viral assembly. Therefore, these two steps are potential targets of antiviral drugs.

Prenylation inhibitors are one example of antiviral drugs that target HDV replication cycle. These drugs have been used in cancer treatment, and are now being studied for hepatitis D treatment.